New drug cocktail shows promise in rare stomach cancer trial
NCT ID NCT06109467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respond to treatment. The approach targets cancers that overexpress HER2, a protein that helps cancer grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Neratinib (a targeted cancer drug) combined with trastuzumab, pembrolizumab, and FOLFOX chemotherapy
What this could lead to
If successful, this could point toward a more effective treatment option for people with HER2-positive gastroesophageal cancers.
What could go wrong
This is a very small, early-phase trial with only 8 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States